| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.8 | -2.0 |
| EPS (diluted, $ a share) | $-0.10 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MRKR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Marker Therapeutics, Inc.: key numbers
- Share price
- $0.8286Close, Nov 16
- Market cap
- $13.8M
- Shares outstanding
- 16.67MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Marker Therapeutics, Inc.
All →Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration
Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.
- Value
- $2.6M
- Counterparty
- Food & Drug Administration